Accepted Manuscript

Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma

Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Meghan Shea, MD, Xiuning Le, MD, PhD, Mark S. Huberman, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD

PII: S1556-0864(17)30014-X

DOI: 10.1016/j.jtho.2016.12.026

Reference: JTHO 481

To appear in: *Journal of Thoracic Oncology*

Received Date: 21 November 2016

Revised Date: 20 December 2016

Accepted Date: 29 December 2016

Please cite this article as: Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB, Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2016.12.026.

Correlation between classic driver oncogene mutations in *EGFR*, *ALK*, or *ROS1* and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma

Deepa Rangachari, MD[1^]; Paul A. VanderLaan, MD, PhD[2^]; Meghan Shea, MD[1]; Xiuning Le, MD, PhD[1]; Mark S. Huberman, MD[1]; Susumu S. Kobayashi, MD, PhD[1]; Daniel B. Costa, MD, PhD[1*]

[1] Department of Medicine, [2] Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

^ these authors contributed equally

Correspondence to:

[*]Daniel B. Costa, MD, PhD - Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Av., Boston, MA 02215
Phone: 617-667-9236
Fax: 617-975-5665
Emails: dbcosta@bidmc.harvard.edu

Running Title: PD-L1 IHC and lack of overlap with driver oncogene mutations

Manuscript type: Brief Report

Keywords: lung cancer; adenocarcinoma; PD-L1; PD-1; pembrolizumab; EGFR; ALK; ROS1; kinase inhibitor; immune checkpoint inhibitor

Funding/Grant Support: This work was funded in part through an American Cancer Society grant RSG 11-186 (DBC), National Cancer Institute grants P50CA090578 (DBC), R01CA169259 (SSK) and R21CA17830 (SSK), and internal donations to Beth Israel Deaconess Medical Center.

Conflict of interest: DBC has received consulting fees and honoraria from Pfizer, Boehringer Ingelheim and Ariad pharmaceuticals; outside the submitted work. PAV has received consulting fees from Gala Therapeutics; outside the submitted work. No other conflict of interest is stated.